Deutsche Bank: Bristol-Myers Squibb's Cardiorenal Meeting Removed from FDA Website

In a research report published today by Deutsche Bank, the tentative Bristol-Myers Squibb's

meeting concerning Cardiorenal has been removed from the FDA's website. Deutsche Bank commented in the report, “Our view has been that this was not likely to happen, but it is possible that an AdComm meeting could be rescheduled to convene the panel for two consecutive days, prior to the end of June, in order to consider both applications. If this is the case, then more information should be forthcoming within the next couple of weeks.” Deutsche Bank maintains its Buy rating and $37.50 PT on Bristol-Myers Squibb, which is currently trading at $32.40.